A Phase 3 interventional study of Efgartigimod PH20 SC and Placebo PH20 SC in Primary Immune Thrombocytopenia, sponsored by argenx. Completed at 200 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-31.
Sponsored by argenx · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Japan — 6 open to participants now, 10 under way, 7 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Japan.
Among the 23 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Japan, this one is the 3rd largest by enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2020, is one of 16 in phase 3, and was the 12th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →6 of the 23 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Japan are open now. Recruiting first, the newest first:
argenx · Sites in Japan, France, Germany and 7 more countries
Ages 12–17
Takeda · Sites in Japan, United States, Australia and 12 more countries
Ages 18+
Takeda · Sites in Japan, United States, Australia and 15 more countries
Ages 18+
Chugai Pharmaceutical · Sites in Japan, United States, Australia and 17 more countries
Ages 18–85
Kissei Pharmaceutical Co., Ltd. · Sites in Japan
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 17
First in 2007; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 207 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 105 across the 21 interventional studies, 355 across the 2 observational. Of the 13 that completed or were terminated, 12 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 23 have an industry lead sponsor. The 10 most frequent:
argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.
argenx has 8 studies filed under Purpura, Thrombocytopenic, Idiopathic — fewer than ten, so there is no comparison to draw.
3 of the studies in Purpura, Thrombocytopenic, Idiopathic with a site in Japan that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07216079Phase 3SanofiRilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan | 2026-11-25 |
| NCT04812925Phase 3argenxA Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | 2027-10 |
| NCT06371417Chugai PharmaceuticalPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 2027-03-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group trial to evaluate the efficacy, safety, and effect on QoL/PRO of efgartigimod PH20 SC treatment in adult patients with primary ITP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Permitted concurrent ITP medications include , danazol, vinca alkaloids, oral , dapsone, fostamatinib, and/or oral TPO-RAs.
-Agree to use measures consistent with local regulations and the protocol
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receiving efgartigimod PH20 SC treatment
Biological: Efgartigimod PH20 SC
Patients receiving placebo PH20 SC treatment
Other: Placebo PH20 SC
Drug pages: Efgartigimod alfa · Hyaluronidase (human recombinant)
Subcutaneous injection with efgartigimod PH20 SC
Also known as: ARGX-113 PH20 SC
Subcutaneous injection with placebo PH20 SC
Percentage of Participants With Chronic Immune Thrombocytopenia (ITP) With a Sustained Platelet Count Response Between Weeks 19 and 24
A participant was considered a responder for this endpoint (i.e., had a sustained platelet count response) if the participant had platelet counts of ≥50 × 10\^9/L for ≥4 of the 6 analysis visits between Weeks 19 and 24.
Time frame: Up to 6 weeks (between Weeks 19 and 24)
Extent of Disease Control Over the 24-Week Treatment Period in the Chronic ITP Population
Extent of disease control was defined as the number of cumulative weeks over the planned 24-week treatment period with platelet counts of ≥50×10\^9/L in the chronic ITP population.
Time frame: Up to 24 weeks
Percentage of Participants in the Overall Population (Chronic and Persistent ITP) With a Sustained Platelet Count Response Between Weeks 19 and 24
A participant was considered a responder for this endpoint (i.e., had a sustained platelet count response) if the participant had platelet counts of ≥50 × 10\^9/L for ≥4 of the 6 analysis visits between Weeks 19 and 24.
Time frame: Up to 6 weeks (between Weeks 19 and 24)
Percentage of Participants in the Overall Population With Sustained Platelet Count Response Between Weeks 17 and 24
A participant was considered a responder for this endpoint (i.e., had a sustained platelet count response) if the participant had platelet counts of ≥50 × 10\^9/L for ≥6 of the 8 analysis visits between weeks 17 and 24.
Time frame: Up to 8 weeks (between Weeks 17 and 24)
Percentage of Participants in the Overall Population Achieving Overall Platelet Count Response at Any Time During the 24-week Treatment Period
A participant was considered a responder for this endpoint (i.e., had an overall platelet count response) if the participant had platelet counts of ≥50 × 10\^9/L for ≥4 analysis visits at any time during the 24-week treatment period.
Time frame: Up to 24 weeks
Extent of Disease Control Until Week 12 in the Overall Population
Extent of disease control was defined as the number of cumulative weeks until Week 12 with platelet counts of ≥50×10\^9/L in the overall population.
Time frame: Up to 12 weeks
Percentage of Participants in the Overall Population Achieving Overall Platelet Count Response at Any Time Until Week 12
A participant was considered a responder for this endpoint (i.e., had an overall platelet count response) if the participant had platelet counts of ≥50 × 10\^9/L for ≥4 analysis visits at any time until Week 12.
Time frame: Up to 12 weeks
Mean Change From Baseline in Platelet Count at Each Visit in the Overall Population
Change from Baseline at time point t = value at time point t - Baseline value. Baseline was defined as the last available value prior to first administration of the investigational medicinal product (IMP).
Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, Safety and Efficacy Follow-up Visit 1 (SEFU1) (up to Week 29), and SEFU2 (up to Week 33)
Time to Platelet Count Response in the Overall Population
Time to platelet count response, defined as the time to have 2 consecutive platelet counts of ≥50 × 10\^9/L via Kaplan-Meier estimates.
Time frame: Up to 24 weeks
Extent of Disease Control Over the 24-Week Treatment Period in the Overall Population
Extent of disease control was defined as the number of cumulative weeks over the planned 24-week treatment period with platelet counts of ≥30×10\^9/L with at least ≥20×10\^9/L above Baseline in the overall population.
Time frame: Up to 24 weeks
Extent of Disease Control Over the 24-Week Treatment Period in the Overall Population for Participants With Baseline Platelet Count of <15×10^9/L
Extent of disease control was defined as the number of cumulative weeks over the planned 24-week treatment period with platelet counts of ≥30×10\^9/L with at least ≥20×10\^9/L above Baseline in the overall population.
Time frame: Up to 24 weeks
Number of the World Health Organization (WHO)-Classified Bleeding Events (Grade ≥1) in the Overall Population
Assessed using the WHO bleeding scale. The WHO bleeding scale is a five-point scale where Grade 0 = no bleeding; Grade 1 = petechial bleeding; Grade 2 = mild blood loss; Grade 3 = gross blood loss (requires transfusion); and Grade 4 = debilitating blood loss, associated with fatality.
Time frame: Up to 24 weeks
Percentage of Participants With a Platelet Count International Working Group (IWG) Response
IWG complete response was defined as platelet counts of ≥100 × 10\^9/L and the absence of bleeding events (WHO Grading = 0 \[no bleeding\]) for at least 2 separate, consecutive analysis visits at least 7 days apart. IWG response was defined as platelet counts of ≥30 × 10\^9/L and a 2-fold increase of platelet count from Baseline and the absence of bleeding events (WHO grading = 0) for at least 2 separate, consecutive analysis visits that were at least 7 days apart. Initial response was defined as platelet counts of ≥30 × 10\^9/L and a 2-fold increase from the Baseline platelet count at analysis visit 5.
Time frame: Up to 24 weeks
Rate of Receipt of Rescue Therapy (Rescue Per Participant Per Month) in the Overall Population
Rescue therapy was defined as an occurrence where the participant needed treatment with 1 or more rescue treatments. An occurrence was defined as a period of maximum 5 days where 1 or more rescue treatments were administered simultaneously or consecutively to the trial participant. The following rescue treatments were permitted: methylprednisolone, dexamethasone, prednisone, normal immunoglobulins, anti-D (Rho) immunoglobins, or platelet transfusions.
Time frame: Up to 24 weeks
Percentage of Participants for Whom Dose and/or Frequency of Concurrent ITP Therapies Have Increased at Week 12 or Later in the Overall Population
A change in ITP therapy was defined as either an increase in the dose and/or frequency of a concurrent ITP therapy relative to Baseline or the initiation of a new concurrent ITP therapy.
Time frame: Up to 13 weeks (between Weeks 12 and 24)
Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue) at Week 24 in the Overall Population
The FACIT-fatigue scale is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during his/her usual daily activities over the past week. The level of fatigue was measured by recording item responses on a 5-point Likert scale ranging from 0 "not at all" to 4 "very much". All items were summed to create a single fatigue score with a range from 0 to 52, where a higher FACIT-F score indicated more severe symptoms. A negative change score from Baseline indicated improvement in quality of life (QoL).
Time frame: Baseline and Week 24
Change From Baseline in Functional Assessment of Cancer Therapy Questionnaire-Th6 (Fact-Th6) at Week 24 in the Overall Population
The FACT-Th6 uses a 5-level Likert scale (0=not at all to 4=very much), with participants rating their degree of concern in the past 7 days. The 6 selected items pertain to ability to do usual activities, worry about problems with bleeding or bruising, worry about the possibility of serious bleeding, avoidance of physical or social activity because of concern with bleeding or bruising and frustration due to the inability to carry out usual activities. All items were summed to create a single score with a range from 0 to 24, where a higher score indicated less severe symptoms. A positive change score from Baseline indicated improvement in QoL.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20, and 24
Change From Baseline in Short Form-36 (SF-36) at Week 24 in the Overall Population
The SF-36 is a 36-item scale constructed to survey health-related QoL on 8 domains: limitations in physical activities due to health problems; limitations in social activities due to physical or emotional problems; limitations in usual role activities due to physical health problems; bodily pain; general mental health (psychological distress and well-being); limitations in usual role activities due to emotional problems; vitality (energy and fatigue); and general health perceptions. The scores from the 8 domains were evaluated independently and aggregated into 2 norm-based summary component measures of physical and mental health. The summary component scores could range from 0 to 100, where a higher score indicated improvement in QoL. A positive change score from Baseline indicated improvement in QoL.
Time frame: Baseline and Week 24
Incidence and Prevalence of Antibodies to Efgartigimod and/or rHuPH20 in the Overall Population
Anti-drug antibody (ADA) incidence was defined as the percentage of participants with treatment-induced or treatment boosted ADA (denominator: number of evaluable participants). ADA prevalence was defined as the percentage of participants with treatment-unaffected ADA, treatment-induced ADA or treatment-boosted ADA (denominator: number of evaluable participants).
Time frame: Up to 35 weeks
Titers of Antibodies to Efgartigimod and/or rHuPH20 in the Overall Population
A titer was determined in the samples with a positive assay response.
Time frame: Weeks 3, 7, 11, 15, 19, 23, 24, SEFU1 (up to Week 29), and SEFU2 (up to Week 33)
Incidence and Prevalence of Neutralizing Antibodies (NAb) to Efgartigimod and/or rHuPH20 in the Overall Population
Samples were tested for the presence of NAb against efgartigimod and/or rHuPH20 and titers for NAb against rHuPH20. NAb incidence is defined as the total percentage of participants with participant classification "baseline negative-postbaseline positive" and "baseline positive-postbaseline positive". NAb prevalence is defined as the total percentage of participants with participant classification "baseline negative-postbaseline positive," "baseline positive-postbaseline positive," or "baseline positive-postbaseline negative".
Time frame: Up to 35 weeks
Serum Efgartigimod Trough Concentration (Ctrough) in the Overall Population
All pharmacokinetic (PK) samples were collected predose, on the day of IMP administration.
Time frame: Predose on Weeks 1, 2, 3, 17, 19, 21, 23, and 24
Percentage Change From Baseline in Total IgG in the Overall Population
Samples were collected predose, on the day of IMP administration.
Time frame: Baseline and Weeks 1, 2, 3, 17, 19, 21, 23, and 24
Number of Participants With Antiplatelet Antibodies in the Overall Population
The antiplatelet antibody was positive if optical density value \>0.129.
Time frame: Weeks 7, 15, 23, and 24
A regionally diverse participant population was enrolled (including but not limited to North America, East Asia, Europe, and the rest of world \[ROW\]). A total of 207 participants were randomized to IMP: 137 participants in the efgartigimod PH20 subcutaneous (SC) arm and 70 participants in the placebo PH20 SC arm.
| Milestone | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Started | 137 | 70 |
| Completed | 113 | 62 |
| Not completed | 24 | 8 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lack of efficacy | 2 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Requires prohibited medication | 2 | 0 |
| Withdrew: Withdrawal of consent | 11 | 6 |
| Withdrew: Miscellaneous | 4 | 1 |
A participant was considered a responder for this endpoint (i.e., had a sustained platelet count response) if the participant had platelet counts of ≥50 × 10\^9/L for ≥4 of the 6 analysis visits between Weeks 19 and 24.
| percentage of participants | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Percentage of Participants With Chronic Immune Thrombocytopenia (ITP) With a Sustained Platelet Count Response Between Weeks 19 and 24 | 13.7 | 16.2 |
Extent of disease control was defined as the number of cumulative weeks over the planned 24-week treatment period with platelet counts of ≥50×10\^9/L in the chronic ITP population.
| weeks | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Extent of Disease Control Over the 24-Week Treatment Period in the Chronic ITP Population | 0.5 (0 to 24) | 0.0 (0 to 23) |
A participant was considered a responder for this endpoint (i.e., had a sustained platelet count response) if the participant had platelet counts of ≥50 × 10\^9/L for ≥4 of the 6 analysis visits between Weeks 19 and 24.
| percentage of participants | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Percentage of Participants in the Overall Population (Chronic and Persistent ITP) With a Sustained Platelet Count Response Between Weeks 19 and 24 | 16.1 | 15.7 |
A participant was considered a responder for this endpoint (i.e., had a sustained platelet count response) if the participant had platelet counts of ≥50 × 10\^9/L for ≥6 of the 8 analysis visits between weeks 17 and 24.
| percentage of participants | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Percentage of Participants in the Overall Population With Sustained Platelet Count Response Between Weeks 17 and 24 | 12.4 | 14.3 |
A participant was considered a responder for this endpoint (i.e., had an overall platelet count response) if the participant had platelet counts of ≥50 × 10\^9/L for ≥4 analysis visits at any time during the 24-week treatment period.
| percentage of participants | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Percentage of Participants in the Overall Population Achieving Overall Platelet Count Response at Any Time During the 24-week Treatment Period | 29.9 | 25.7 |
Extent of disease control was defined as the number of cumulative weeks until Week 12 with platelet counts of ≥50×10\^9/L in the overall population.
| weeks | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Extent of Disease Control Until Week 12 in the Overall Population | 0.00 (0.00 to 12.00) | 0.00 (0.00 to 11.00) |
A participant was considered a responder for this endpoint (i.e., had an overall platelet count response) if the participant had platelet counts of ≥50 × 10\^9/L for ≥4 analysis visits at any time until Week 12.
| percentage of participants | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Percentage of Participants in the Overall Population Achieving Overall Platelet Count Response at Any Time Until Week 12 | 18.2 | 15.7 |
Change from Baseline at time point t = value at time point t - Baseline value. Baseline was defined as the last available value prior to first administration of the investigational medicinal product (IMP).
| platelets x10^9/L | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Week 1 | 13.84 ± 41.150 | 8.82 ± 34.355 |
| Week 2 | 16.62 ± 49.408 | 23.54 ± 85.005 |
| Week 3 | 17.07 ± 39.855 | 19.22 ± 71.947 |
| Week 4 | 12.39 ± 37.886 | 9.31 ± 26.813 |
| Week 5 | 18.14 ± 54.335 | 12.24 ± 30.059 |
| Week 6 | 34.61 ± 112.204 | 16.35 ± 40.891 |
| Week 7 | 28.25 ± 107.932 | 13.46 ± 41.876 |
| Week 8 | 21.77 ± 52.308 | 16.57 ± 42.508 |
| Week 9 | 19.90 ± 54.542 | 20.42 ± 53.488 |
| Week 10 | 21.73 ± 47.685 | 15.42 ± 33.119 |
| Week 11 | 20.13 ± 42.193 | 14.54 ± 25.588 |
| Week 12 | 21.02 ± 43.882 | 22.28 ± 56.173 |
| Week 13 | 22.29 ± 44.654 | 15.51 ± 37.651 |
| Week 14 | 23.60 ± 47.521 | 24.04 ± 55.678 |
| Week 15 | 21.30 ± 45.776 | 28.05 ± 67.897 |
| Week 16 | 30.32 ± 71.553 | 23.09 ± 46.154 |
| Week 17 | 25.12 ± 54.747 | 30.05 ± 56.581 |
| Week 18 | 28.54 ± 53.115 | 31.64 ± 57.309 |
| Week 19 | 33.86 ± 59.323 | 37.26 ± 68.832 |
| Week 20 | 30.87 ± 55.342 | 25.85 ± 48.409 |
| Week 21 | 30.04 ± 61.438 | 26.23 ± 50.323 |
| Week 22 | 33.26 ± 61.558 | 29.23 ± 55.175 |
| Week 23 | 29.51 ± 53.437 | 24.89 ± 41.103 |
| Week 24 | 25.51 ± 52.203 | 24.91 ± 42.972 |
| SEFU1 | 40.44 ± 64.860 | 48.70 ± NA |
| SEFU2 | 30.00 ± 35.011 | 56.25 ± 85.206 |
Time to platelet count response, defined as the time to have 2 consecutive platelet counts of ≥50 × 10\^9/L via Kaplan-Meier estimates.
| days | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Time to Platelet Count Response in the Overall Population | NA (155.0 to NA) | NA (NA to NA) |
Extent of disease control was defined as the number of cumulative weeks over the planned 24-week treatment period with platelet counts of ≥30×10\^9/L with at least ≥20×10\^9/L above Baseline in the overall population.
| weeks | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Extent of Disease Control Over the 24-Week Treatment Period in the Overall Population | 1.0 (0 to 24) | 1.0 (0 to 24) |
Extent of disease control was defined as the number of cumulative weeks over the planned 24-week treatment period with platelet counts of ≥30×10\^9/L with at least ≥20×10\^9/L above Baseline in the overall population.
| weeks | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Extent of Disease Control Over the 24-Week Treatment Period in the Overall Population for Participants With Baseline Platelet Count of <15×10^9/L | 1.0 (0 to 23) | 0.0 (0.0 to 24) |
Assessed using the WHO bleeding scale. The WHO bleeding scale is a five-point scale where Grade 0 = no bleeding; Grade 1 = petechial bleeding; Grade 2 = mild blood loss; Grade 3 = gross blood loss (requires transfusion); and Grade 4 = debilitating blood loss, associated with fatality.
| bleeding events | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Number of the World Health Organization (WHO)-Classified Bleeding Events (Grade ≥1) in the Overall Population | 9.0 (0 to 24) | 10.0 (0 to 24) |
IWG complete response was defined as platelet counts of ≥100 × 10\^9/L and the absence of bleeding events (WHO Grading = 0 \[no bleeding\]) for at least 2 separate, consecutive analysis visits at least 7 days apart. IWG response was defined as platelet counts of ≥30 × 10\^9/L and a 2-fold increase of platelet count from Baseline and the absence of bleeding events (WHO grading = 0) for at least 2 separate, consecutive analysis visits that were at least 7 days apart. Initial response was defined as platelet counts of ≥30 × 10\^9/L and a 2-fold increase from the Baseline platelet count at analysis visit 5.
| percentage of participants | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| IWG Complete Response | 10.2 | 11.4 |
| IWG Response | 28.5 | 20.0 |
| Initial Response | 19.7 | 17.1 |
Rescue therapy was defined as an occurrence where the participant needed treatment with 1 or more rescue treatments. An occurrence was defined as a period of maximum 5 days where 1 or more rescue treatments were administered simultaneously or consecutively to the trial participant. The following rescue treatments were permitted: methylprednisolone, dexamethasone, prednisone, normal immunoglobulins, anti-D (Rho) immunoglobins, or platelet transfusions.
| rescues per participant per month | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Rate of Receipt of Rescue Therapy (Rescue Per Participant Per Month) in the Overall Population | 0.25 ± 0.553 | 0.17 ± 0.363 |
A change in ITP therapy was defined as either an increase in the dose and/or frequency of a concurrent ITP therapy relative to Baseline or the initiation of a new concurrent ITP therapy.
| percentage of participants | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Percentage of Participants for Whom Dose and/or Frequency of Concurrent ITP Therapies Have Increased at Week 12 or Later in the Overall Population | 11.7 | 15.7 |
The FACIT-fatigue scale is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during his/her usual daily activities over the past week. The level of fatigue was measured by recording item responses on a 5-point Likert scale ranging from 0 "not at all" to 4 "very much". All items were summed to create a single fatigue score with a range from 0 to 52, where a higher FACIT-F score indicated more severe symptoms. A negative change score from Baseline indicated improvement in quality of life (QoL).
| score on a scale | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue) at Week 24 in the Overall Population | -0.025 ± 0.712 | 0.741 ± 0.985 |
The FACT-Th6 uses a 5-level Likert scale (0=not at all to 4=very much), with participants rating their degree of concern in the past 7 days. The 6 selected items pertain to ability to do usual activities, worry about problems with bleeding or bruising, worry about the possibility of serious bleeding, avoidance of physical or social activity because of concern with bleeding or bruising and frustration due to the inability to carry out usual activities. All items were summed to create a single score with a range from 0 to 24, where a higher score indicated less severe symptoms. A positive change score from Baseline indicated improvement in QoL.
| score on a scale | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Change From Baseline in Functional Assessment of Cancer Therapy Questionnaire-Th6 (Fact-Th6) at Week 24 in the Overall Population | 0.225 ± 0.360 | 0.359 ± 0.498 |
The SF-36 is a 36-item scale constructed to survey health-related QoL on 8 domains: limitations in physical activities due to health problems; limitations in social activities due to physical or emotional problems; limitations in usual role activities due to physical health problems; bodily pain; general mental health (psychological distress and well-being); limitations in usual role activities due to emotional problems; vitality (energy and fatigue); and general health perceptions. The scores from the 8 domains were evaluated independently and aggregated into 2 norm-based summary component measures of physical and mental health. The summary component scores could range from 0 to 100, where a higher score indicated improvement in QoL. A positive change score from Baseline indicated improvement in QoL.
| score on a scale | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Week 24: Mental Component | 1.215 ± 0.620 | 0.957 ± 0.841 |
| Week 24: Physical Component | -0.848 ± 0.525 | -0.850 ± 0.712 |
Anti-drug antibody (ADA) incidence was defined as the percentage of participants with treatment-induced or treatment boosted ADA (denominator: number of evaluable participants). ADA prevalence was defined as the percentage of participants with treatment-unaffected ADA, treatment-induced ADA or treatment-boosted ADA (denominator: number of evaluable participants).
| percentage of participants | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Incidence of Antibodies to Efgartigimod | 5.1 | 2.9 |
| Prevalence of Antibodies to Efgartigimod | 16.2 | 7.1 |
| Incidence of Antibodies to rHuPH20 | 41.2 | 20.0 |
| Prevalence of Antibodies to rHuPH20 | 50.0 | 31.4 |
A titer was determined in the samples with a positive assay response.
| titer | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Week 3: ADA Against Efgartigimod Titer | — | 16.5 ± 15.50 |
| Week 7: ADA Against Efgartigimod Titer | 1.0 ± NA | 11.3 ± 10.33 |
| Week 11: ADA Against Efgartigimod Titer | — | 6.3 ± 4.84 |
| Week 15: ADA Against Efgartigimod Titer | — | 8.5 ± 7.50 |
| Week 23: ADA Against Efgartigimod Titer | — | 2.0 ± NA |
| Week 24: ADA Against Efgartigimod Titer | 16.3 ± 8.95 | 1.0 ± 0.00 |
| SEFU1: ADA Against Efgartigimod Titer | 2.5 ± 1.50 | — |
| SEFU2: ADA Against Efgartigimod Titer | 17.0 ± 15.00 | — |
| Week 3: ADA Against rHuPH20 Titer | 12.7 ± 2.53 | 14.1 ± 3.15 |
| Week 7: ADA Against rHuPH20 Titer | 645.9 ± 314.79 | 14.4 ± 4.27 |
| Week 11: ADA Against rHuPH20 Titer | 2204.8 ± 1297.43 | 11.4 ± 2.37 |
| Week 15: ADA Against rHuPH20 Titer | 3209.3 ± 1325.96 | 15.7 ± 2.02 |
| Week 19: ADA Against rHuPH20 Titer | 3742.7 ± 1414.15 | 49.1 ± 27.87 |
| Week 23: ADA Against rHuPH20 Titer | 5936.6 ± 2180.33 | 58.3 ± 27.83 |
| Week 24: ADA Against rHuPH20 Titer | 4731.3 ± 1898.96 | 69.1 ± 26.60 |
| SEFU1: ADA Against rHuPH20 Titer | 5122.5 ± 5117.50 | — |
| SEFU2: ADA Against rHuPH20 Titer | 5160.0 ± 5080.00 | — |
Samples were tested for the presence of NAb against efgartigimod and/or rHuPH20 and titers for NAb against rHuPH20. NAb incidence is defined as the total percentage of participants with participant classification "baseline negative-postbaseline positive" and "baseline positive-postbaseline positive". NAb prevalence is defined as the total percentage of participants with participant classification "baseline negative-postbaseline positive," "baseline positive-postbaseline positive," or "baseline positive-postbaseline negative".
| percentage of participants | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Incidence of NAb to Efgartigimod | 0.7 | 0.0 |
| Prevalence of NAb to Efgartigimod | 5.1 | 0.0 |
| Incidence of NAb to rHuPH20 | 0.0 | 0.0 |
| Prevalence of NAb to rHuPH20 | 0.0 | 0.0 |
All pharmacokinetic (PK) samples were collected predose, on the day of IMP administration.
| μg/mL | Efgartigimod PH20 SC |
|---|---|
| Week 1 | 13.2 ± 6.46 |
| Week 2 | 16.6 ± 8.17 |
| Week 3 | 17.0 ± 7.95 |
| Week 17 | 15.1 ± 8.54 |
| Week 19 | 15.4 ± 7.43 |
| Week 21 | 15.1 ± 8.86 |
| Week 23 | 14.9 ± 7.79 |
| Week 24 | 14.7 ± 8.10 |
Samples were collected predose, on the day of IMP administration.
| percentage of total IgG | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Week 1 | -33.64 ± 26.018 | 0.60 ± 14.065 |
| Week 2 | -50.68 ± 34.973 | 10.31 ± 44.858 |
| Week 3 | -56.80 ± 39.133 | 4.97 ± 28.484 |
| Week 17 | -64.76 ± 11.478 | 1.27 ± 16.749 |
| Week 19 | -60.98 ± 26.460 | 9.28 ± 44.989 |
| Week 21 | -62.38 ± 15.176 | 4.62 ± 25.406 |
| Week 23 | -62.45 ± 20.286 | 2.45 ± 21.271 |
| Week 24 | -61.97 ± 18.200 | -0.36 ± 17.408 |
The antiplatelet antibody was positive if optical density value \>0.129.
| Participants | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Week 7 | 20 | 10 |
| Week 15 | 18 | 10 |
| Week 23 | 17 | 9 |
| Week 24 | 19 | 8 |
Collected over Up to 35 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Efgartigimod PH20 SC | 1/137 (0.7%) | 14/137 (10.2%) | 130/137 (94.9%) |
| Placebo PH20 SC | 0/70 (0%) | 10/70 (14.3%) | 65/70 (92.9%) |
| Event | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 1/137 | 2/70 |
| HaematuriaRenal and urinary disorders | 0/137 | 2/70 |
| COVID-19Infections and infestations | 3/137 | 0/70 |
| HeadacheNervous system disorders | 2/137 | 0/70 |
| Autoimmune thyroiditisEndocrine disorders | 0/137 | 1/70 |
| Inguinal hernia strangulatedGastrointestinal disorders | 0/137 | 1/70 |
| Arthritis infectiveInfections and infestations | 0/137 | 1/70 |
| Head injuryInjury, poisoning and procedural complications | 0/137 | 1/70 |
| Platelet count decreasedInvestigations | 0/137 | 1/70 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 0/137 | 1/70 |
| Event | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| HaematuriaRenal and urinary disorders | 32/137 | 23/70 |
| Blood urine presentInvestigations | 43/137 | 20/70 |
| EcchymosisSkin and subcutaneous tissue disorders | 34/137 | 20/70 |
| PetechiaeSkin and subcutaneous tissue disorders | 34/137 | 19/70 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 20/137 | 15/70 |
| Injection site haemorrhageGeneral disorders | 14/137 | 14/70 |
| ContusionInjury, poisoning and procedural complications | 22/137 | 12/70 |
| PurpuraSkin and subcutaneous tissue disorders | 15/137 | 11/70 |
| Gingival bleedingGastrointestinal disorders | 14/137 | 10/70 |
| Mouth haemorrhageGastrointestinal disorders | 19/137 | 6/70 |
Safety Analysis Set (SAF): All participants who received at least 1 dose or part of a dose.
| Age, Continuous(years) | Efgartigimod PH20 SC | Placebo PH20 SC | Total |
|---|---|---|---|
| Mean | 47.3 ± 17.22 | 50.0 ± 15.29 | 48.2 ± 16.60 |
| Sex: Female, Male(Participants) | Efgartigimod PH20 SC | Placebo PH20 SC | Total |
|---|---|---|---|
| Female | 88 | 43 | 131 |
| Male | 49 | 27 | 76 |
| Ethnicity (NIH/OMB)(Participants) | Efgartigimod PH20 SC | Placebo PH20 SC | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 2 | 10 |
| Not Hispanic or Latino | 129 | 68 | 197 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Efgartigimod PH20 SC | Placebo PH20 SC | Total |
|---|---|---|---|
| Asian | 44 | 18 | 62 |
| Black or African American | 4 | 2 | 6 |
| White | 88 | 49 | 137 |
| Other | 1 | 1 | 2 |
Showing the first 100 of 200 sites across 32 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Dec 2020 to primary completion in Oct 2023, 33 months.
Results were first posted in Oct 2024, 1 year after primary completion.
Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 33 months is above that.
Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Efgartigimod alfa · Hyaluronidase (human recombinant)
Purpura, Thrombocytopenic, Idiopathic →